Nucleic Acids Therapeutics - Making Sense of Antisense
July 28, 2016
Session 7 of the 2016 Drug Design and Delivery Symposium
Unmodified oligonucleotides are highly charged, polyanionic macromolecules with poor drug-like properties and a lot of potential. Tune in as Punit Seth of Ionis describes the use of chemical modification strategies to enhance the stability, binding affinity, pharmacokinetic and toxicological properties of oligonucleotide drugs.
What You Will Learn
- General design principles for making an oligonucleotide drug
- Chemical modification strategies to enhance drug-like properties of oligonucleotide drugs
- Recent developments in targeted delivery of oligonucleotide therapeutics
Additional Resources
- Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRASin Bladder Cancer Cells through a Decoy Mechanism - ACS Medicinal Chemistry Letters
- Conjugation and Evaluation of Small Hydrophobic Molecules to Triazole-Linked siRNAs - ACS Medicinal Chemistry Letters
- Synthetic Nucleic Acid Delivery Systems: Present and Perspectives - Journal of Medicinal Chemistry
- Oligonucleotide Analogues as Modulators of the Expression and Function of Noncoding RNAs (ncRNAs): Emerging Therapeutics Applications - Journal of Medicinal Chemistry
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.
Experts
Punit Seth
Ionis Pharmaceuticals
Richard Olson
Bristol-Myers Squibb
Co-Produced By
;void(0);){kind=link}